MedtronicMDT
About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Employees: 95,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
64% more first-time investments, than exits
New positions opened: 205 | Existing positions closed: 125
39% more funds holding in top 10
Funds holding in top 10: 31 [Q4 2024] → 43 (+12) [Q1 2025]
17% more repeat investments, than reductions
Existing positions increased: 922 | Existing positions reduced: 787
14% more capital invested
Capital invested by funds: $85.1B [Q4 2024] → $96.9B (+$11.9B) [Q1 2025]
2% more funds holding
Funds holding: 2,089 [Q4 2024] → 2,127 (+38) [Q1 2025]
1% more call options, than puts
Call options by funds: $1.05B | Put options by funds: $1.04B
0.18% less ownership
Funds ownership: 83.02% [Q4 2024] → 82.84% (-0.18%) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Citigroup Joanne Wuensch | 10%upside $99 | Buy Maintained | 9 Jul 2025 |
Evercore ISI Group Vijay Kumar | 18%upside $106 | Outperform Maintained | 8 Jul 2025 |
Leerink Partners Mike Kratky | 22%upside $110 | Outperform Initiated | 16 Jun 2025 |
Mizuho Anthony Petrone | 9%upside $98 | Outperform Maintained | 22 May 2025 |
RBC Capital Shagun Singh | 12%upside $101 | Outperform Maintained | 22 May 2025 |
Financial journalist opinion
Based on 21 articles about MDT published over the past 30 days









